136 related articles for article (PubMed ID: 7736542)
1. Immunotargeting of urothelial cell carcinoma with intravesically administered Tc-99m labeled HMFG1 monoclonal antibody.
Malamitsi J; Zorzos J; Varvarigou AD; Archimandritis S; Dassiou C; Sivolapenko G; Skarlos DV; Serefoglou A; Lykourinas M; Proukakis C
Cell Biophys; 1994; 24-25():75-81. PubMed ID: 7736542
[TBL] [Abstract][Full Text] [Related]
2. Immunolocalization of transitional cell carcinoma of the bladder with intravesically administered technetium-99m labelled HMFG1 monoclonal antibody.
Malamitsi J; Zorzos J; Varvarigou AD; Archimandritis S; Dassiou C; Skarlos DV; Dimitriou P; Likourinas M; Zizi A; Proukakis C
Eur J Nucl Med; 1995 Jan; 22(1):25-31. PubMed ID: 7698151
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibodies for intravesical radioimmunotherapy of human bladder cancer.
Russell PJ; Plomley J; Shon IH; O'Grady H; Pearce N
Cell Biophys; 1993; 22(1-3):27-47. PubMed ID: 7889541
[TBL] [Abstract][Full Text] [Related]
4. Intravesical administration of radiolabelled tumour-associated monoclonal antibody in bladder cancer.
Syrigos KN; Khawaja M; Krausz T; Williams G; Epenetos AA
Acta Oncol; 1999; 38(3):379-82. PubMed ID: 10380831
[TBL] [Abstract][Full Text] [Related]
5. Intravesical administration of tumor-associated monoclonal antibody AUA1 in transitional cell carcinoma of the bladder: a study of biodistribution.
Zorzos J; Skarlos DV; Epenetos AA; Pectasides D; Koutsioumba P; Elemenoglou J; Bakiras A; Likourinas M; Dimopoulos K
Urol Res; 1993; 21(6):435-8. PubMed ID: 8171767
[TBL] [Abstract][Full Text] [Related]
6. Intravesical administration of radiolabeled antitumor monoclonal antibody in bladder carcinoma.
Bamias A; Keane P; Krausz T; Williams G; Epenetos AA
Cancer Res; 1991 Jan; 51(2):724-8. PubMed ID: 1985790
[TBL] [Abstract][Full Text] [Related]
7. (99m)Tc-labeled murine ior C5 monoclonal antibody in colorectal carcinoma patients: pharmacokinetics, biodistribution, absorbed radiation doses to normal organs and tissues and tumor localization.
Iznaga-Escobar N; Ramos-Suzarte M; Morales-Morales A; Torres-Arocha L; Rodríguez-Mesa N; Pérez-Rodriguez R
Methods Find Exp Clin Pharmacol; 2004 Nov; 26(9):687-96. PubMed ID: 15632954
[TBL] [Abstract][Full Text] [Related]
8. Intravesical alpha-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice.
Pfost B; Seidl C; Autenrieth M; Saur D; Bruchertseifer F; Morgenstern A; Schwaiger M; Senekowitsch-Schmidtke R
J Nucl Med; 2009 Oct; 50(10):1700-8. PubMed ID: 19793735
[TBL] [Abstract][Full Text] [Related]
9. Intravesical administration of indium-111-labelled HMFG2 monoclonal antibody in superficial bladder carcinomas.
Bamias A; Bowles MJ; Krausz T; Williams G; Epenetos AA
Int J Cancer; 1993 Jul; 54(6):899-903. PubMed ID: 8335396
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, biodistribution, and dosimetry of specific and control radiolabeled monoclonal antibodies in patients with primary head and neck squamous cell carcinoma.
Maraveyas A; Stafford N; Rowlinson-Busza G; Stewart JS; Epenetos AA
Cancer Res; 1995 Mar; 55(5):1060-9. PubMed ID: 7866989
[TBL] [Abstract][Full Text] [Related]
11. Epithelial mucin expression in bladder cancer: correlation with pathological and clinical parameters.
Syrigos KN; Deonarain DM; Karayiannakis A; Waxman J; Krausz T; Pignatelli M
Urol Res; 2000 Aug; 28(4):241-5. PubMed ID: 11011962
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical and immunocytochemical study of bladder carcinomas using the epithelium-specific, tumour-associated monoclonal antibodies HMFG1 and AUA1.
Anagnostaki E; Skarlos D; Tamvakis N; Psaropoulou P; Blana E; Bamias A; Legaki S; Aravantinos G; Deliveliotis C; Dimopoulos K
Br J Cancer Suppl; 1990 Jul; 10():52-6. PubMed ID: 2200496
[TBL] [Abstract][Full Text] [Related]
13. Intravesical administration of EGF- dextran conjugates in patients with superficial bladder cancer.
Bue P; Holmberg AR; Márquez M; Westlin JE; Nilsson S; Malmström PU
Eur Urol; 2000 Nov; 38(5):584-9. PubMed ID: 11096240
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis and management of superficial bladder cancer.
Amling CL
Curr Probl Cancer; 2001; 25(4):219-78. PubMed ID: 11514784
[TBL] [Abstract][Full Text] [Related]
15. Antibody drug carrier for immunotherapy of superficial bladder cancer: ultrastructural studies.
de Harven E; Fradet Y; Connolly JG; Hanna W; He S; Wang Y; Choi BC; McGroarty R; Bootsma G; Tilups A
Cancer Res; 1992 Jun; 52(11):3131-7. PubMed ID: 1591726
[TBL] [Abstract][Full Text] [Related]
16. [Multiorgan failure following intravesical bacillus Calmette-Guerin administration: a case report].
Baba Y; Ishizu K; Jojima K; Joko K; Nakamura K; Takihara H; Naito K
Hinyokika Kiyo; 1992 Sep; 38(9):1063-5. PubMed ID: 1414761
[TBL] [Abstract][Full Text] [Related]
17. Immunoscintigraphy with iodine-131-labelled monoclonal antibody AUA1 in patients with transitional cell carcinoma of the bladder.
Zorzos J; Skarlos DV; Pozatzidou P; Zizi A; Bakiras A; Koritsiadis S; Pectasidis D; Koutsioumba P; Epenetos AA; Likourinas M
Urol Res; 1994; 22(5):323-7. PubMed ID: 7879319
[TBL] [Abstract][Full Text] [Related]
18. Detection of transitional cell carcinoma in bladder by intravesical injection of monoclonal antibodies.
Chopin DK; deKernion JB
Urol Res; 1986; 14(3):145-8. PubMed ID: 3529570
[TBL] [Abstract][Full Text] [Related]
19. [Current status of the treatment of urothelial tumors].
Akaza H
Gan To Kagaku Ryoho; 1988 Feb; 15(2):205-11. PubMed ID: 3341782
[TBL] [Abstract][Full Text] [Related]
20. Localization of avidin in superficial bladder cancer: a potentially new approach for radionuclide therapy.
Chinol M; De Cobelli O; Trifirò G; Scardino E; Bartolomei M; Verweij F; Papi S; Matei DV; Paganelli G
Eur Urol; 2003 Nov; 44(5):556-9. PubMed ID: 14572754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
